About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
D
Brentuximab Vedotin + AVD vs. ABVD in Advanced cHL: What Is the 5-Year Update of the ECHELON-1?
By
David Straus
6 Videos
85 views
May 12, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
Featured Video
08:18
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…
Feat.
A. Zhou
Related Content
AUTOPLAY
ON
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
16:25
Northwestern Medicine Oncology and Hematology
Diagnosis and Goals of Therapy in PV
Feat.
B. Stein
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
10:49
Monia Marchetti
Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…
05:24
2021 ASCO Virtual Direct™ Highlights
2021 ASCO Key Takeaways on Lymphoma: Selected Trials on CLL & HL…
Feat.
M. Kamdar
01:24
Total Health
ASCO 2022 Updates in Lymphoma and CLL
Feat.
W. Hammond
07:31
UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Updates on cHL: 2L Pembro + GVD, Brentuximab Vedotin & Check…
Feat.
P. Riedell
08:30
i3 Health
Treatment Strategies for Advanced cHL: Predictive & Prognostic M…
Feat.
K. Maddocks,
K. Brassil
17:34
2021 ASCO Virtual Direct™ Highlights
ASCO 2021 Q&A Session on Key Clinical Data in Leukemia & Lym…
Feat.
C. McMahon,
M. Kamdar
11:25
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)
SOHO 2021 Next Questions in Hodgkin Lymphoma
Feat.
C. Moskowitz
17:46
Penn Medicine's 2021 Updates in Care of the Hematologic Malignancies Patient
UPenn Expert Discussion on Lymphoma: Efficacy of Acalabrutinib for S…
Feat.
S. Schuster,
J. Gerson,
J. Svoboda,
E. Chong,
S. Nasta,
D. Beach,
G. Hanna
38:27
Judith Ann Ferry
Classical Hodgkin Lymphoma: Subtypes and Differential Diagnosis
19:53
Judith Ann Ferry
Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): Clinical an…
32:02
2021 ASCO Virtual Direct™ Highlights
ASCO 2021 Q&A Session on New Updates in Hematologic Malignancies
Feat.
D. Maloney,
M. Percival
22:32
2021 ASCO Virtual Direct™ Highlights
2021 ASCO Q&A on Practice-Changing Abstracts in Lymphoma and Leu…
Feat.
J. Soumerai,
T. Kadia
19:41
2021 ASCO Virtual Direct™ Highlights
2021 ASCO Lymphoma and Leukemia Q&A Session: Impact of Recent Tr…
Feat.
J. Svoboda,
R. Redner
35:19
NYU Langone
Targeted Treatment Strategies in Hematologic Malignancies
Feat.
T. Moskovits
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
